Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Outcome of AGM 8 Sep
-
Dispatch Of Letter To Shareholders With Web-Link Of Notice Of AGM And Annual Report 2024-25
3 Sep - Dispatched letter with weblink to 31st AGM notice and FY2024-25 Annual Report; AGM Sept 8, 2025, 4:00 PM (VC).
- Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Aug
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
8 Aug - Q1 FY26 standalone results approved; Company Secretary Hasan Bohra resigned effective Aug 8, 2025.
- Financial Results For June, 2025 8 Aug
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments